Sense Biodetection has signed a strategic agreement with Abacus dx for the non-exclusive distribution of its Veros instrument-free, point-of-care molecular Covid-19 test in Australia and New Zealand.
Claimed to be the first and only self-contained, single-use Covid-19 product, Veros produces PCR-quality molecular results in around 15 minutes without the need for an external power supply or reader.
It uses rapid molecular amplification technology and aims to improve access to quick, accurate, point-of-care testing.
